Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The interest coverage ratio is N/A as of Tuesday, October 6, 2026.
INTEREST COVERAGE RATIO
N/A
Market Cap
$198.33M
Interest Coverage Ratio
N/A
TTM Avg
4.80x
3Y Avg
4.80x
5Y Avg
4.80x
Market Cap
$192.49M
Interest Coverage Ratio
-1204.75x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$190.07M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$189.11M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$205.80M
Interest Coverage Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$207.27M
Interest Coverage Ratio
16.00x
TTM Avg
14.45x
3Y Avg
13.14x
5Y Avg
13.02x
| NAME | MARKET CAP | INTEREST COVERAGE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Surrozen, Inc. (SRZN) | $197.18M | N/A | N/A | N/A | N/A |
| Exagen Inc. (XGN)vs › | $197.87M | -3.26x | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $198.33M | N/A | 4.80x | 4.80x | 4.80x |
| Alector, Inc. (ALEC)vs › | $200.96M | N/A | N/A | N/A | N/A |
| RxSight, Inc. (RXST)vs › | $192.49M | -1204.75x | N/A | N/A | N/A |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $190.07M | N/A | N/A | N/A | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.11M | N/A | N/A | N/A | N/A |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 16.00x | 14.45x | 13.14x | 13.02x |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
Interest Coverage
N/A
Debt/Equity
N/A
Current Ratio
12.14
Formula: Interest Coverage = EBIT / Interest Expense
Reference ranges:
Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.
Interest Coverage = EBIT / Interest Expense
The interest coverage ratio measures operating earnings relative to interest expense.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
